Co-Innovation Biotech

Executive Summary

Co-Innovation Biotech is a preclinical-stage, research-driven biotechnology company based in Shanghai, China, focused on developing first-in-class and best-in-class therapeutics in oncology, neuroscience, and metabolic diseases. Founded in 2010, the company employs a collaborative model, partnering with academic institutions and other biotechs to advance its pipeline of small molecules and biologics. Despite its long history, the company remains in early stages with no disclosed pipeline details, suggesting a cautious approach to development. The lack of public information on funding, valuation, or specific programs limits visibility into its progress. However, its broad therapeutic focus and collaborative strategy may position it for future breakthroughs if key programs advance to clinical development. The company has minimal online presence and no reported commercial products, indicating a need for substantial de-risking before it can attract significant investment or partnerships.

Upcoming Catalysts (preview)

• Q2 2027Lead program IND filing in oncology40% success
• Q4 2026New partnership with academic institution in neuroscience50% success
• Q3 2026Preclinical data release for metabolic disease candidate45% success